A live cold-recombinant influenza B virus vaccine (RB77) was given intranasally in a placebo-controlled, double blind study to volunteers in dosages of 10(7.9) EID50/ml, 10(7.25) EID50/ml, 10(5.7) EID50/ml. The tolerability, safety, and immunogenicity of the vaccine were investigated. No revertant virus was found in nasal swabs taken after immunisation. Local reactions were mild and showed a significant increase over the placebo only in the highest dose group. Systemic reactions were not different from the placebo. A significant increase in haemagglutinin inhibition titre was found in the highest dose group against the immunising strain (RB77) and the two wild strains B/TEC and B/Sing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.1890250211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccines for preventing influenza in people with asthma.
Cochrane Database Syst Rev
February 2013
Population Health Sciences and Education, St George’s, University of London, London,
Background: Influenza vaccination is recommended for asthmatic patients in many countries as observational studies have shown that influenza infection can be associated with asthma exacerbations. However, influenza vaccination has the potential to cause wheezing and adversely affect pulmonary function. While an overview concluded that there was no clear benefit of influenza vaccination in patients with asthma, this conclusion was not based on a systematic search of the literature.
View Article and Find Full Text PDFInfluenza virus infections in infants.
Pediatr Infect Dis J
November 1997
Influenza Research Center, Department of Microbiology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Background: Universal immunization of children with live attenuated cold recombinant vaccine has been proposed. The renewed recommendation for maternal immunization with influenza vaccine should increase the amount of antibody transmitted to the infant and postpone the need for active immunization. This study examines the risk of influenza during the first year of life to provide information about the time to initiate active immunization.
View Article and Find Full Text PDFCytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine.
J Med Virol
October 1996
Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
The cytotoxic T lymphocyte (CTL) response of infants after immunization with either inactivated trivalent subvirion vaccine (TIV) or bivalent attenuated cold-recombinant (CR) vaccine or occurrence of natural influenza virus infection were compared in a blinded, placebo-controlled study during the 1987-1988 and 1988-1989 influenza epidemic seasons. Healthy infants between 6 and 13 months of age were randomly assigned and administered a single dose of intranasal bivalent (A/H3N2/A/H1N1) CR vaccine, a two-dose regimen of TIV (A/H3N2/A/H1N1/B) influenza vaccine, or placebo. Peripheral blood lymphocytes were obtained prior to and 2-8 weeks after vaccination and at the end of the epidemic season and stimulated with virus in vitro for 6 or 7 days.
View Article and Find Full Text PDFGene analysis of reassortant influenza virus by RT-PCR followed by restriction enzyme digestion.
J Virol Methods
February 1996
Chemo-Sero-Therapeutic Research Institute, Shimizu Laboratory 668, Kumamoto, Japan.
An amplification system for nearly full length cDNA coding the eight influenza virus segments of A type (H1N1, H2N2, H3N2) and B type influenza viruses is described. Each of the segments of PB1, PB2, PA, NP, M, and NS can be amplified using one 5' primer and one 3' primer for A-type influenza viruses. The RT-PCR amplification system was applied to define the gene composition of three subtype cold-recombinant, live attenuated influenza viruses.
View Article and Find Full Text PDFPrevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response.
Vaccine
February 1995
Department of Pediatrics, Kochi Medical School, Japan.
To clarify which immunological factors were more effective in preventing influenza virus infection, we measured immunological parameters induced by vaccination and infection in vivo and in vitro. Healthy adult subjects (n = 128) were divided into vaccinated (n = 85) and untreated (n = 43) groups. Eighty-five were vaccinated intranasally with a trivalent cold-adapted recombinant influenza virus vaccine containing type A (H1N1 and H3N2) and B viruses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!